Ironwood Pharmaceuticals (IRWD) EV to CFO (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EV to CFO across 17 years of filings, most recently posting 10.58 for Q2 2026.

• In Q2 2026, EV to CFO rose 761.45% year-over-year to 10.58; the TTM figure through Jun 2026 stood at 3.32 (up 313.39% YoY), while the FY2025 annual figure was 2.63, down 56.17% from the prior year.
• EV to CFO came in at 10.58 for Q2 2026 at Ironwood Pharmaceuticals, down from 69.78 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 69.78 in Q1 2026 to a low of 1.6 in Q2 2025.
• Average EV to CFO over 5 years is 25.65, with a median of 20.85 recorded in 2022.
• Year-over-year, EV to CFO slumped 105.72% in 2025 and surged 976.15% in 2026.
• Over 5 years, EV to CFO stood at 15.8 in 2022, then surged by 199.69% to 47.34 in 2023, then decreased by 13.76% to 40.83 in 2024, then sank by 89.03% to 4.48 in 2025, then soared by 136.18% to 10.58 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 10.58 in Q2 2026, 69.78 in Q1 2026, and 4.48 in Q4 2025.